Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | TPMT | P51580 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197207 | 1.00 | KDM4E (0.47) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7184528 | 0.84 | PBRM1 (0.42) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL475757 | 0.83 | TTR (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2820215 | 0.83 | KDM4E (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL109155 | 0.83 | KDM4E (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL23501889 | 0.83 | TTR (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL8361 | 0.83 | TTR (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL223304 | 0.83 | KDM4E (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL15484864 | 0.82 | PARP1 (0.52) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11153457 | 0.80 | TTR (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751962-A | Preparation method of heat radiation aerogel for lithium battery | 广东宇阳新能源有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-118179544-B | Preparation method of propane dehydrogenation catalyst | 烟台百川汇通科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118179544-A | Preparation method of propane dehydrogenation catalyst | 烟台百川汇通科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-114621191-B | EZH2 inhibitor and preparation and application thereof | 东南大学 | 2023-08-15 | — | — | CN | claimed |
| CN-114621191-A | EZH2 inhibitor and preparation and application thereof | 东南大学 | 2022-06-14 | — | — | CN | claimed |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| CN-119751962-A | Preparation method of heat radiation aerogel for lithium battery | 广东宇阳新能源有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-115698020-B | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2025-02-25 | — | — | CN | disclosed |
| CN-119264055-A | WDR5 inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| EP-4434522-A2 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-2103618-A1 | Novel ansamitocin derivatives | Leibniz Universität Hannover (DE) | 2009-09-23 | — | — | EP | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | PCNA, POLL, DNA2 | KDM4E 3490/4885MEN1 3594/4885KMT2A 700/4885 |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | KDM4E 1761/4885MEN1 1556/4885KMT2A 2989/4885 |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | KDM4E 4123/4885MEN1 1403/4885KMT2A 3726/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | KDM4E 3518/4885MEN1 3378/4885KMT2A 2994/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | KDM4E 4652/4885MEN1 31/4885KMT2A 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.